AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10457579 — intervention group
Group type: COMPARATOR
Intervention: Control group (experience without intervention)
Number of subjects: 77
Study 7543083 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mmol magnesium sulfate infusion over 20 hours
Number of subjects: 252
Study 7543083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 2475689 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg verapamil HCl sustained‐release tablet (Isoptin SR 240, Securon SR)
Number of subjects: 10
Study 2475689 — intervention group
Group type: COMPARATOR
Intervention: two half 240‐mg verapamil HCl sustained‐release tablets (2 X half 240‐mg tablets, Study 1)
Number of subjects: 10
Study 2475689 — intervention group
Group type: COMPARATOR
Intervention: two 120-mg verapamil HCl sustained‐release tablets (Isoptin SR 120) (2 X 120 mg, Study 2)
Number of subjects: 10
Study 31808151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg.kg-1
Number of subjects: 51
Study 31808151 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 51
Study 29277690 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β2 agonists, long-acting muscarinic antagonists (LABAs or LAMAs), LABA/LAMA combination QVA149
Number of subjects: 23213
Study 29277690 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments (including LABA/LAMA)
Number of subjects: 23213
Study 29277690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23213
Study 28251729 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 79
Study 28251729 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 79
Study 25644340 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain (WG) diet (>80 g/d)
Number of subjects: 33
Study 25644340 — intervention group
Group type: COMPARATOR
Intervention: Refined grain (RG) diet (<16 g/d)
Number of subjects: 33
Study 24325834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 42
Study 24325834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 42
Study 24325834 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 21310691 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed actions
Number of subjects: 0
Study 21310691 — intervention group
Group type: COMPARATOR
Intervention: Observed actions
Number of subjects: 0
Study 21310691 — intervention group
Group type: COMPARATOR
Intervention: Active recall during retrieval practice
Number of subjects: 0
Study 18315425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation plus application of an 8.8% doxycycline gel
Number of subjects: 32
Study 18315425 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic instrumentation alone
Number of subjects: 32
Study 18315425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 18315425 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antibiotic therapy (doxycycline)
Number of subjects: 32
Study 17195531 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenical (120 mg 3 times a day) with moderate hypocaloric diet
Number of subjects: 75
Study 17195531 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypocaloric diet
Number of subjects: 75
Study 12749501 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar strokes
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-artery strokes
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes in symptomatic artery territory
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-artery strokes in symptomatic artery territory
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes in asymptomatic artery territory
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar strokes in asymptomatic artery territory
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-artery strokes in asymptomatic artery territory
Number of subjects: 2885
Study 10732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Strokes unrelated to carotid stenosis
Number of subjects: 2885
Study 8629921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle joint movement perception threshold (JMPT) assessment using a device designed for this study.
Number of subjects: 51
Study 8629921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous sensory function measurement for vibration perception using a vibrometer and touch-pressure perception using Semmes-Weinstein monofilaments.
Number of subjects: 51
Study 1444931 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-modulated noise (160 Hz)
Number of subjects: 100
Study 1444931 — intervention group
Group type: COMPARATOR
Intervention: Filtered-random noise (600 Hz)
Number of subjects: 100
Study 6204202 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive food challenges (up to 8 g of dehydrated food)
Number of subjects: 33
Study 6204202 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenges (60 total)
Number of subjects: 33
Study 6204202 — intervention group
Group type: COMPARATOR
Intervention: Negative food challenges (41 total)
Number of subjects: 33
Study 30797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority condition (one child eating raspberries)
Number of subjects: 0
Study 30797120 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no food presented)
Number of subjects: 0
Study 30797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority condition (all children eating raspberries)
Number of subjects: 0
Study 29547834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored FEC (E 75-90 mg/m2, C 900-1200 mg/m2)
Number of subjects: 1535
Study 29547834 — intervention group
Group type: COMPARATOR
Intervention: Standard FEC (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Number of subjects: 1535
Study 29547834 — intervention group
Group type: COMPARATOR
Intervention: Registered cohort (standard FEC for grade 3-4 leukopenia)
Number of subjects: 1535
Study 26710243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir (300 mg)
Number of subjects: 125
Study 26710243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir with ritonavir (multiple doses)
Number of subjects: 125
Study 26710243 — intervention group
Group type: COMPARATOR
Intervention: Paritaprevir (single dose)
Number of subjects: 125
Study 26710243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 24898637 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropostural optimization (NPO) protocol
Number of subjects: 60
Study 24898637 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 60
Study 24898637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NPO and Sham protocols
Number of subjects: 60
Study 22576861 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal (Reliance)
Number of subjects: 75
Study 22576861 — intervention group
Group type: EXPERIMENTAL
Intervention: CervitecPlus (Ivoclar Vivadent)
Number of subjects: 75
Study 22576861 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Cure® (Reliance)
Number of subjects: 75
Study 22576861 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex® gelée (GABA)
Number of subjects: 75
Study 22576861 — intervention group
Group type: COMPARATOR
Intervention: non-treated control group
Number of subjects: 75
Study 20218761 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a brief presentation, brochure for parents, educational video, and sun protection incentives for children.
Number of subjects: 197
Study 20218761 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 197
Study 18833128 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloinhalation therapy
Number of subjects: 125
Study 16253904 — intervention group
Group type: EXPERIMENTAL
Intervention: LA circumferential ablation
Number of subjects: 80
Study 16253904 — intervention group
Group type: COMPARATOR
Intervention: Nonencircling linear ablation
Number of subjects: 80
Study 12161081 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals promoting CONSORT
Number of subjects: 105
Study 12161081 — intervention group
Group type: COMPARATOR
Intervention: Journals not promoting CONSORT
Number of subjects: 105
Study 11783143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared rhubarb
Number of subjects: 0
Study 11783143 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (Control)
Number of subjects: 0
Study 7762505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study 7762505 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 0
Study 2317421 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 90 minutes
Number of subjects: 0
Study 2317421 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 120 minutes
Number of subjects: 0
Study 2317421 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for less than 120 minutes
Number of subjects: 0
Study 387170 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 387170 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 387170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 387170 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 30553766 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX) performing a 20-min aerobic and coordinative exercise session on each school day for 8 weeks
Number of subjects: 36
Study 30553766 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) encouraged to have social interactions
Number of subjects: 36
Study 30553766 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX)
Number of subjects: 36
Study 30553766 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study 27753157 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (n=101)
Number of subjects: 136
Study 27753157 — intervention group
Group type: COMPARATOR
Intervention: Delayed activation control (n=35)
Number of subjects: 136
Study 27753157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (baseline and 12-month comparisons)
Number of subjects: 136
Study 26175226 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + cPR
Number of subjects: 27
Study 26175226 — intervention group
Group type: COMPARATOR
Intervention: Sham + cPR
Number of subjects: 27
Study 24099414 — intervention group
Group type: EXPERIMENTAL
Intervention: Falloon Psychoeducation Program (FPP)
Number of subjects: 340
Study 24099414 — intervention group
Group type: COMPARATOR
Intervention: Family supportive therapy with generic information
Number of subjects: 340
Study 20840875 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in clinical trials (cases)
Number of subjects: 184
Study 20840875 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer treatments (controls)
Number of subjects: 184
Study 20840875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cases and controls)
Number of subjects: 184
Study 18502382 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for abdominal aortic aneurysms (AAAs)
Number of subjects: 0
Study 18502382 — intervention group
Group type: EXPERIMENTAL
Intervention: Various screening methods
Number of subjects: 0
Study 16223206 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin 1,200 mg/day
Number of subjects: 18
Study 16223206 — intervention group
Group type: COMPARATOR
Intervention: lactulose 10-20 g three times daily
Number of subjects: 18
Study 16223206 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 12169045 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine/Placebo
Number of subjects: 24
Study 12169045 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine/Ketoconazole
Number of subjects: 24
Study 10550153 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐CRA) 30 mg orally daily for 6 months
Number of subjects: 44
Study 10550153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7495926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 2 mg
Number of subjects: 14
Study 7495926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2180267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0
Study 2180267 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 2180267 — intervention group
Group type: COMPARATOR
Intervention: Fibrates
Number of subjects: 0
Study 2180267 — intervention group
Group type: COMPARATOR
Intervention: Control agents (cholestyramine, fibrates, probucol)
Number of subjects: 0
Study 424477 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐flupenthixol
Number of subjects: 41
Study 424477 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐flupenthixol
Number of subjects: 41
Study 424477 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 424477 — intervention group
Group type: EXPERIMENTAL
Intervention: active medication (alpha‐flupenthixol)
Number of subjects: 41
Study 424477 — intervention group
Group type: EXPERIMENTAL
Intervention: non-habituation of skin conductance
Number of subjects: 41
Study 424477 — intervention group
Group type: EXPERIMENTAL
Intervention: insidious onset (Feighner negative patients)
Number of subjects: 41
Study 31199837 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 6185
Study 28953616 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) administered 30 minutes before induction of anesthesia
Number of subjects: 136
Study 28953616 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) administered immediately after induction of anesthesia
Number of subjects: 136
Study 28953616 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 136
Study 25704429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 210
Study 25704429 — intervention group
Group type: COMPARATOR
Intervention: Nonbursectomy
Number of subjects: 210
Study 23368980 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (morphine, oxycodone)
Number of subjects: 35
Study 23368980 — intervention group
Group type: COMPARATOR
Intervention: Non-opioids (placebo)
Number of subjects: 35
Study 21425574 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Qianyang Pellet (MQYP)
Number of subjects: 48
Study 21425574 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic treatment + fluid resuscitation)
Number of subjects: 48
Study 19588638 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination gel containing BPO 5% and clindamycin 1% (BPO/C) plus tretinoin microsphere gel 0.04% (RAM)
Number of subjects: 0
Study 19588638 — intervention group
Group type: COMPARATOR
Intervention: Fixed-combination gel containing clindamycin phosphate 1.2% and tretinoin 0.025% (CPT) plus a once-daily BPO 5% wash
Number of subjects: 0
Study 17382640 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier ring
Number of subjects: 356
Study 17382640 — intervention group
Group type: COMPARATOR
Intervention: Duran ring
Number of subjects: 356
Study 17382640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 356
Study 15069024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioners added to general practice teams
Number of subjects: 48
Study 15069024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nurse practitioners)
Number of subjects: 48
Study 11177037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 48
Study 11177037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9609934 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet analysis of click-evoked otoacoustic emissions (CEOAE's)
Number of subjects: 0
Study 9609934 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet transform applied to CEOAE's
Number of subjects: 0
Study 7813389 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC) 1500 mg/day for 90 days
Number of subjects: 481
Study 7813389 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 30 days (phase T0) and further 30 days of placebo treatment (phase T3)
Number of subjects: 481
Study 2898167 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at night
Number of subjects: 8
Study 2898167 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 8
Study 2898167 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at night
Number of subjects: 8
Study 2898167 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine twice daily
Number of subjects: 8
Study 2898167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30289098 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographic promotion on social media
Number of subjects: 24
Study 30289098 — intervention group
Group type: COMPARATOR
Intervention: Control group (screen capture image of article’s abstract)
Number of subjects: 24
Study 29133325 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MISS) - mini-open decompression with bilateral interbody fusion and percutaneous pedicle screw fixation
Number of subjects: 184
Study 29133325 — intervention group
Group type: COMPARATOR
Intervention: Open surgery - conventional surgery with decompression and instrumented fusion with pedicle screws and bilateral interbody fusion
Number of subjects: 184
Study 29133325 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MISS)
Number of subjects: 184
Study 29133325 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 184
Study 25752401 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-based isotoxic accelerated radiation therapy (PET-ART)
Number of subjects: 200
Study 25752401 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed-dose CT-based radiation therapy (CRT)
Number of subjects: 200
Study 24166906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 105
Study 21406465 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term abstinence (3-30 days)
Number of subjects: 0
Study 21406465 — intervention group
Group type: COMPARATOR
Intervention: Long-term abstinence (3-24 months)
Number of subjects: 0
Study 21406465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress induced by the Trier Social Stress Test
Number of subjects: 0
Study 21406465 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg) administered 1 hour before stress
Number of subjects: 0
Study 18201356 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment twice/week
Number of subjects: 20
Study 18201356 — intervention group
Group type: COMPARATOR
Intervention: PUVA treatment three times/week
Number of subjects: 20
Study 15356084 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/d, 3 months)
Number of subjects: 36
Study 15356084 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 36
Study 15356084 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E)
Number of subjects: 36
Study 15356084 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T)
Number of subjects: 36
Study 11458055 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Number of subjects: 547
Study 11458055 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Number of subjects: 547
Study 11458055 — intervention group
Group type: COMPARATOR
Intervention: 3-month neoadjuvant hormonal therapy
Number of subjects: 547
Study 11458055 — intervention group
Group type: COMPARATOR
Intervention: 8-month neoadjuvant hormonal therapy
Number of subjects: 547
Study 9558128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg VPA daily
Number of subjects: 16
Study 9558128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg VPA daily
Number of subjects: 16
Study 8051603 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected risk factors (prognosis, restricted activity days, presence of hearing and speech problems, perceived unpredictability of symptoms)
Number of subjects: 286
Study 8051603 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents' perceptions of the impact of the condition
Number of subjects: 286
Study 8051603 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Symptom Index
Number of subjects: 286
Study 2977273 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex 3.6 mg depot
Number of subjects: 193
Study 2977273 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 3 mg/day
Number of subjects: 193
Study 28873028 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraoperative dose of IV acetaminophen
Number of subjects: 260
Study 28873028 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative pain regimen (oral acetaminophen and ibuprofen)
Number of subjects: 260
Study 27074894 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 40 mL of 0.375% levobupivacaine and morphine patient‐controlled analgesia
Number of subjects: 52
Study 27074894 — intervention group
Group type: COMPARATOR
Intervention: Morphine patient‐controlled analgesia (Control)
Number of subjects: 52
Study 27074894 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 52
Study 25294064 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive child obesity intervention program
Number of subjects: 1860